DTIL
Precision Biosciences Inc
$9.25
+1.01 (+12.26%)
At close · Jul 7
Market Cap
$233.64M
Shares
25,802,247
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.25
Open$8.24
Day$8.03–9.62
52W$3.53–9.62
Avg vol 30d525K
Short int1.9M · 7.5% float · 5.4d
Short vol39%
Last earningsMar 12, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 5
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.1 · calm
Equity put/call 0.69
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+60%
above
Price vs 50-day avg
+29%
above
RSI (14)
76
overbought
MACD trend
Positive
52-week position
94%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+42%
trailing
6-month return
+128%
trailing
YTD return
+122%
this year
Relative strength
+120%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +21 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.53% of float · ▲ +16.1% MoM · 5.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
78 holders — near 2-yr high, broad support
Squeeze score
75
high risk · 0–100
Fundamentals
EPS growth
−442%
Y/Y
Balance sheet
$88.6M
net cash
Quant / Vol
risk profile
Volatility
70%
annualized · 1-yr
Max drawdown
−59%
past year
ATR
6.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ1-27 quarter ends
~Aug 21, 2026
Est
filed May 5, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+60%
Bullish
Price vs 50-day avg
+29%
Bullish
RSI (14)
76
Bearish
MACD trend
Positive
Bullish
52-week position
94%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +21 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.53% of float · ▲ +16.1% MoM · 5.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
78 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $4
Now $9 · 94%
52-wk high $10
vs 200-day avg +60%
vs 50-day avg +29%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DTIL
this stock
Precision Biosciences Inc
|
$233.64M | +122.4% | -50.1% | — | 7.5% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DTIL | +16.8% | +42.3% | +127.8% | +17.7% | +122.4% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +15.9% | +40.9% | +120.3% | +17.6% | +112.7% |